openPR Logo
Press release

Niemann-Pick Disease Type C Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Zevra Therapeutics, Azafaros A.G, IntraBio, Cyclo Therapeutics, Azafaros A.G

08-23-2024 09:38 PM CET | Health & Medicine

Press release from: DelveIinsight Business Research

Niemann-Pick Disease Type C Market Forecasted to Surge in Coming

DelveInsight's "Niemann-Pick Disease Type C Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Niemann-Pick Disease Type C, historical and forecasted epidemiology as well as the Niemann-Pick Disease Type C market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Niemann-Pick Disease Type C market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Niemann-Pick Disease Type C Market Forecast
https://www.delveinsight.com/sample-request/niemann-pick-disease-type-c-npc-market-insights-epidemiology-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Niemann-Pick Disease Type C Market Report:
• The Niemann-Pick Disease Type C market size was valued ~34 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
• The market size for Niemann-Pick Disease Type C (NPC) in the US was USD 9 million in 2022. According to DelveInsight's analysis, the market is expected to grow due to the rising prevalence of the disease.
• In January 2023, Azafaros has received IND approval and is currently conducting Phase II trials to assess the safety and pharmacokinetic profile in patients with NPC.
• DelveInsight's analysis shows that the market size for Niemann-Pick Disease Type C in the EU-4 and the UK was around USD 23 million in 2022. This market is projected to grow during the forecast period from 2023 to 2034.
• According to DelveInsight's analysis, there were 787 diagnosed prevalent cases of Niemann-Pick Disease Type C in the 7MM in 2022, with a projected increase in cases expected during the forecast period of 2023 to 2034.
• In 2022, the EU4 countries and the UK accounted for 328 cases of Niemann-Pick Disease Type C. Among these countries, Germany had the highest number of diagnosed prevalent cases, with 84 cases, representing 26% of the total in these four European nations. This number is expected to rise during the study period from 2020 to 2034.
• In 2022, Spain had the lowest number of diagnosed prevalent cases of Niemann-Pick Disease Type C among the EU4 countries.
• The diagnosed prevalent cases of Niemann-Pick Disease Type C in the 7MM differed by gender, with females having higher numbers than males. According to DelveInsight's analysts, there were 433 diagnosed prevalent cases in females and 354 in males in 2022. These numbers are expected to increase during the forecast period from 2023 to 2034.
• According to DelveInsight's analysts, Japan had 37 diagnosed prevalent cases of the juvenile type (ages 6 to under 15) of Niemann-Pick Disease Type C in 2022.
• In 2022, the market size for Niemann-Pick Disease Type C (NPC) in Japan was USD 2 million, representing 6% of the total market size across the 7MM. It is anticipated to increase by 2034.
• Key Niemann-Pick Disease Type C Companies: Zevra Therapeutics, Azafaros A.G, IntraBio, Cyclo Therapeutics, Azafaros A.G., and others
• Key Niemann-Pick Disease Type C Therapies: Arimoclomol, AZ-3102, IB1001, N-Acetyl-L-Leucine, Hydroxypropyl-beta-cyclodextrin, AZ-3102, and others
• The Niemann-Pick Disease Type C epidemiology based on gender analyzed that Niemann Pick Disease Type C is more prevalent in females than in males
• The Niemann-Pick Disease Type C market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Niemann-Pick Disease Type C pipeline products will significantly revolutionize the Niemann-Pick Disease Type C market dynamics.

Niemann-Pick Disease Type C Overview
Niemann-Pick Disease Type C (NPC) is a rare, inherited, neurodegenerative disorder characterized by the abnormal accumulation of lipids (fats) in various tissues of the body, particularly in the brain, liver, and spleen. This accumulation is due to mutations in the NPC1 or NPC2 genes, which are responsible for regulating the transport of cholesterol and other lipids within cells. These mutations disrupt the normal processing and movement of lipids, leading to their buildup and subsequent cellular dysfunction and damage.

Get a Free sample for the Niemann-Pick Disease Type C Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/niemann-pick-disease-type-c-npc-market-insights-epidemiology-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Niemann-Pick Disease Type C Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Niemann-Pick Disease Type C Epidemiology Segmentation:
The Niemann-Pick Disease Type C market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Niemann-Pick Disease Type C
• Prevalent Cases of Niemann-Pick Disease Type C by severity
• Gender-specific Prevalence of Niemann-Pick Disease Type C
• Diagnosed Cases of Episodic and Chronic Niemann-Pick Disease Type C

Download the report to understand which factors are driving Niemann-Pick Disease Type C epidemiology trends @ Niemann-Pick Disease Type C Epidemiology Forecast
https://www.delveinsight.com/sample-request/niemann-pick-disease-type-c-npc-market-insights-epidemiology-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Niemann-Pick Disease Type C Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Niemann-Pick Disease Type C market or expected to get launched during the study period. The analysis covers Niemann-Pick Disease Type C market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Niemann-Pick Disease Type C Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Niemann-Pick Disease Type C Therapies and Key Companies
• Arimoclomol: Zevra Therapeutics
• AZ-3102: Azafaros A.G
• IB1001: IntraBio
• N-Acetyl-L-Leucine: IntraBio Inc
• arimoclomol: ZevraDenmark
• Hydroxypropyl-beta-cyclodextrin: Cyclo Therapeutics
• AZ-3102: Azafaros A.G.

Discover more about therapies set to grab major Niemann-Pick Disease Type C market share @ Niemann-Pick Disease Type C Treatment Landscape
https://www.delveinsight.com/sample-request/niemann-pick-disease-type-c-npc-market-insights-epidemiology-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Niemann-Pick Disease Type C Market Drivers
• Advances in genetic testing and diagnostic technologies
• Increasing awareness and improved disease identification
• Rising prevalence of NPC globally
• Growing research and development initiatives for novel therapies
• Supportive regulatory environment facilitating drug approvals
• Expansion of healthcare infrastructure and accessibility

Niemann-Pick Disease Type C Market Barriers
• Limited understanding of disease mechanisms and variability
• High costs associated with treatment and care
• Challenges in early diagnosis and screening
• Limited therapeutic options and efficacy of current treatments
• Regulatory complexities in drug development and approval
• Accessibility issues in healthcare systems, especially in developing regions

Scope of the Niemann-Pick Disease Type C Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Niemann-Pick Disease Type C Companies: Zevra Therapeutics, Azafaros A.G, IntraBio, Cyclo Therapeutics, Azafaros A.G., and others
• Key Niemann-Pick Disease Type C Therapies: Arimoclomol, AZ-3102, IB1001, N-Acetyl-L-Leucine, Hydroxypropyl-beta-cyclodextrin, AZ-3102, and others
• Niemann-Pick Disease Type C Therapeutic Assessment: Niemann-Pick Disease Type C current marketed and Niemann-Pick Disease Type C emerging therapies
• Niemann-Pick Disease Type C Market Dynamics: Niemann-Pick Disease Type C market drivers and Niemann-Pick Disease Type C market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Niemann-Pick Disease Type C Unmet Needs, KOL's views, Analyst's views, Niemann-Pick Disease Type C Market Access and Reimbursement

To know more about Niemann-Pick Disease Type C companies working in the treatment market, visit @ Niemann-Pick Disease Type C Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/niemann-pick-disease-type-c-npc-market-insights-epidemiology-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Niemann-Pick Disease Type C Market Report Introduction
2. Executive Summary for Niemann-Pick Disease Type C
3. SWOT analysis of Niemann-Pick Disease Type C
4. Niemann-Pick Disease Type C Patient Share (%) Overview at a Glance
5. Niemann-Pick Disease Type C Market Overview at a Glance
6. Niemann-Pick Disease Type C Disease Background and Overview
7. Niemann-Pick Disease Type C Epidemiology and Patient Population
8. Country-Specific Patient Population of Niemann-Pick Disease Type C
9. Niemann-Pick Disease Type C Current Treatment and Medical Practices
10. Niemann-Pick Disease Type C Unmet Needs
11. Niemann-Pick Disease Type C Emerging Therapies
12. Niemann-Pick Disease Type C Market Outlook
13. Country-Wise Niemann-Pick Disease Type C Market Analysis (2020-2034)
14. Niemann-Pick Disease Type C Market Access and Reimbursement of Therapies
15. Niemann-Pick Disease Type C Market Drivers
16. Niemann-Pick Disease Type C Market Barriers
17. Niemann-Pick Disease Type C Appendix
18. Niemann-Pick Disease Type C Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:

Niemann-Pick Disease Type C Pipeline https://www.delveinsight.com/report-store/niemann-pick-type-c-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Niemann-Pick Disease Type C Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Niemann-Pick Disease Type C market. A detailed picture of the Niemann-Pick Disease Type C pipeline landscape is provided, which includes the disease overview and Niemann-Pick Disease Type C treatment guidelines.

Latest Reports by DelveInsight

Idiopathic Thrombocytopenic Purpura Market
https://www.delveinsight.com/report-store/idiopathic-thrombocytopenic-purpura-market
DelveInsight's "Idiopathic Thrombocytopenic Purpura Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Idiopathic Thrombocytopenic Purpura, historical and forecasted epidemiology as well as the Idiopathic Thrombocytopenic Purpura market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Inguinal Hernia Market
https://www.delveinsight.com/report-store/inguinal-hernia-market
DelveInsight's "Inguinal Hernia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Inguinal Hernia, historical and forecasted epidemiology as well as the Inguinal Hernia market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Charcot-marie-tooth Disease Market
https://www.delveinsight.com/report-store/charcot-marie-tooth-disease-market
DelveInsight's 'Charcot-Marie-Tooth Disease Market Insights, Epidemiology, and Market Forecast 2032' report deliver an in-depth understanding of the Charcot-Marie-Tooth Disease, historical and forecasted epidemiology as well as the Charcot-Marie-Tooth Disease market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Listeriosis Market
https://www.delveinsight.com/report-store/listeriosis-market
DelveInsight's comprehensive report titled "Listeriosis Market Insights, Epidemiology, and Market Forecast - 2034" offers a detailed analysis of Listeriosis. The report presents historical and projected epidemiological data covering incident cases of listeriosis, age-specific cases of listeriosis, gender-specific cases of listeriosis, risk-associated cases of listeriosis, and treated cases of listeriosis.

Dysfunctional Uterine Bleeding Market
https://www.delveinsight.com/report-store/dysfunctional-uterine-bleeding-market
DelveInsight's "Dysfunctional Uterine Bleeding Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Dysfunctional Uterine Bleeding, historical and forecasted epidemiology as well as the Dysfunctional Uterine Bleeding market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Mrna Based Vaccines And Therapeutics Market
https://www.delveinsight.com/report-store/global-messenger-rna-mrna-based-vaccines-and-therapeutics-market
DelveInsight's "Global Messenger RNA (mRNA)-based Vaccines and Therapeutics- Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Global Messenger RNA (mRNA)-based Vaccines and Therapeutics, historical and forecasted epidemiology as well as the Global Messenger RNA (mRNA)-based Vaccines and Therapeutics market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Papilloma Market
https://www.delveinsight.com/report-store/papilloma-market
DelveInsight's "Papilloma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Papilloma, historical and forecasted epidemiology as well as the Papilloma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Periodontal Disease Market
https://www.delveinsight.com/report-store/periodontal-disease-market
DelveInsight's "Periodontal Disease Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Periodontal Disease, historical and forecasted epidemiology as well as the Periodontal Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Niemann-Pick Disease Type C Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Zevra Therapeutics, Azafaros A.G, IntraBio, Cyclo Therapeutics, Azafaros A.G here

News-ID: 3633354 • Views:

More Releases from DelveIinsight Business Research

Advanced Renal Cell Carcinoma Market Report 2034: Epidemiology Data, Therapies, Latest Drug Approvals | DelveInsight | Pfizer, AbbVie, Bristol-Myers Squibb, Abbott, Takeda, Amgen, Novartis, AVEO Pharma, Calithera Biosciences, Inc, Merck Sharp & Dohme LLC
Advanced Renal Cell Carcinoma Market Report 2034: Epidemiology Data, Therapies, …
DelveInsight's "Advanced Renal Cell Carcinoma Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Antibody Drug Conjugates, historical and forecasted epidemiology as well as the Antibody Drug Conjugates market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Advanced Renal Cell Carcinoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Advanced Renal
PCSK9 Inhibitors Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Novo Nordisk, AstraZeneca, Sirnaomics, Vaxxinity, Verve Therapeutics, Xinlitai Biotech
PCSK9 Inhibitors Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, PCSK9 Inhibitors pipeline constitutes 14+ key companies continuously working towards developing 14+ PCSK9 Inhibitors treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "PCSK9 Inhibitors Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the PCSK9 Inhibitors Market. The PCSK9
Metastatic Prostate Cancer Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Curium, Merck/ Orion, Pfizer, AstraZeneca, Telix Pharma, Tavanta Therapeutics, Candel Therapeutics
Metastatic Prostate Cancer Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clin …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Metastatic Prostate Cancer pipeline constitutes 75+ key companies continuously working towards developing 75+ Metastatic Prostate Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Metastatic Prostate Cancer Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Metastatic Prostate
Bunion (Hallux Valgus) Market to Expand Significantly by 2034, States DelveInsight Report | Heron Therapeutics, Lotus Clinical Research, Cali Pharma, Grünenthal GmbH, Pacira Pharma, Inc, Mallinckrodt, Cali Pharma
Bunion (Hallux Valgus) Market to Expand Significantly by 2034, States DelveInsig …
DelveInsight's "Bunion Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Bunion, historical and forecasted epidemiology as well as the Bunion market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Bunion market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Bunion Market Forecast https://www.delveinsight.com/sample-request/hallux-valgus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Some of the key facts of the Bunion

All 5 Releases


More Releases for Disease

Protheragen Announces Disease Model Development Services to Enhance Rare Disease …
Protheragen announced the release of its disease model development services provided to enhance rare disease research. With an increasing focus on rare diseases and the need for tailored research models, Protheragen is dedicated to providing cutting-edge solutions to support this important area of medical research. Rare diseases, which affect a small percentage of the population, pose unique challenges for researchers due to their limited understanding and lack of available treatment options.
Biopharmaceutical Fermentation Market 2022 | Growing Morbidity of Genetic Diseas …
According to Precision Business Insights (PBI), the latest report, the biopharmaceutical fermentation market is expected to be valued at USD 10,302.1 million in 2022, growing at a 4.7% CAGR from 2022 to 2028. The growing prevalence of chronic illness, cancer, cardiac diseases, infectious diseases, antibiotic resistance, autoimmune diseases, etc., globally causes the leaning toward biopharmaceutical products, which show promising results in the research studies. Moreover, new findings by the
Global Inflammatory Bowel Disease (IBD) Market Key Players Analysis, Disease Ind …
Global Inflammatory Bowel Disease (IBD) Market, valued at USD 210.5 Billion in the year 2020 has been driven by factors such as the increasing prevalence of Ulcerative Colitis and Crohn’s Disease, advances in medical technology, government support for inflammatory bowel disease treatment research, and the ubiquity of anxiety and depression. Moreover, factors such as the irregular food habits, unhealthy lifestyle of people, increased level of pollution and increase in alcohol
Moyamoya Disease Market - A Scientometric Assessment of Disease During 2018-23
Market Highlight: Moyamoya disease (MMD) is a chronic, cerebrovascular disease characterized by progressive stenosis in the internal carotid artery and an abnormal vascular network at the base of the brain. The stroke is one of the significant symptoms of moyamoya disease, which further leads to paralysis of the face, arms, and legs, loss of speech, and temporary loss of neurologic function of body parts, visual disturbances, headaches, developmental delay, and
Refsum Disease Industry An Overview of A New Disease - 2018
"Refsum Disease" is a genetic disorder which is inherited as an autosomal recessive trait. The condition is characterized by progressive loss of vision (retinitis pigmentosa), failure of muscle coordination (ataxia), degenerative nerve disease (peripheral neuropathy), and dry, rough, scaly skin (ichthyosis). The accumulation of fatty acid (phytanic acid) in blood plasma and tissues is the main cause of refsum disease. This occurs due to malfunction of the enzyme producing gene
Chagas Disease (Infectious Disease) Pipeline Forecast Report, H1, 2017 [MRH]
Market Research Hub's Pharmaceutical and Healthcare latest pipeline guide Chagas Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chagas Disease Market (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and